Takeda’s Vonicog Alfa Receives NMPA Approval for Von Willebrand Disease Treatment in China
Takeda Pharmaceutical Company Limited (TYO: 4502 / NYSE: TAK), a leading Japanese pharmaceutical company, has...
Takeda
Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort
Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
Takeda Reports 3.7% YOY Revenue Growth in Q1 2023 Fiscal Year with Priority Products Driving Sales
Japan-based multinational Takeda (TYO: 4502) has released its financial report for the fiscal year 2023...
Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review
Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the...
Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...
Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502,...
Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials
Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced...
Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories
Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an...
Degron Therapeutics Partners with Takeda for Molecular Glue Degraders Development
Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and...
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...
Takeda Strikes Deal with AC Immune for Global Rights to Alzheimer’s Immunotherapies
Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA...
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...
HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...
Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline
Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this...